Company Profile

Two of the principals of Accuronix Therapeutics for over a decade have collaborated to extend the discoveries of one of them in the arena of the ?-2 receptor in cancer cells into the development of novel therapeutic modalities for pancreatic adenocarcinoma and a wide range of other tumor types. With an initial focus in pancreatic cancer, the Company’s mission is to develop novel oncology therapies based on technology that selectively targets ?-2 receptors overexpressed on cancer cells - applying a novel drug-targeting technology to some of the most difficult problems in cancer therapy